Daniel J George, MD

Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71. Abstract

De Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005. Abstract

Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983-92. Abstract

Montgomery BR et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-54. Abstract

Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25(6):947-70. Abstract

Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48. Abstract

Van der Goes MC et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-9. Abstract

Robert Dreicer, MD, MS

Clegg NJ et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72(6):1494-503. Abstract

Efstathiou E et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. Genitourinary Cancers Symposium 2011;Abstract 4501.

Scher HI et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375(9724):1437-46. Abstract

A Oliver Sartor, MD

Bruland ØS et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12(20 Pt 2):6250s-7s. Abstract

Henriksen G et al. Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003;44(2):252-9. Abstract

McDevitt MR et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25(9):1341-51. Abstract

Parker C et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Proc ASCO 2012;Abstract LBA4512.

Celestia S Higano, MD

Drake CG et al. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10(8):580-93. Abstract

Higano CS et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. Proc ASCO 2010;Abstract 4550.

Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22. Abstract

Madan RA et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol 2012;13(5):501-8. Abstract

Small EJ et al. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. Proc ASCO 2011;Abstract 4661.

Christopher J Logothetis, MD

Chi KN et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97(17):1287-96. Abstract

Corn PG. The tumor microenvironment in prostate cancer: Elucidating molecular pathways for therapy development. Cancer Manag and Res 2012;4:183-93. Abstract

Park SI et al. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68(9):3323-33. Abstract

Tzelepi V et al. Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. Proc ASCO 2010;Abstract 4663.